In vitro biological activity of cobalt(II) complexes with salicylaldimine ligands in microbial and cancer cells

Future Med Chem. 2023 Aug;15(15):1415-1426. doi: 10.4155/fmc-2023-0190. Epub 2023 Aug 16.

Abstract

Background: More studies using cobalt complexes as drugs are needed. Results: The drug action of two cobalt salicylaldimines was determined. The complexes and amphotericin B (20 mg/ml) inhibited Candida albicans at 9-15 and 21 mm. This concentration of both ligands inhibited Staphylococcus aureus at 10 mm and one ligand inhibited Escherichia coli at 9 mm, but the complexes and ampicillin inhibited four bacteria at 9-20 and 21-26 mm. The ligands were inactive against cancer and normal cells, but the complexes and doxorubicin provided IC50 values of 28.18-54.19 and 9.66 μM against MCF-7 cells and 15.76-20.49 and 36.42 μM against BHK cells. Conclusion: The ligands' activity was much improved by complexation, although they remained substandard.

Keywords: Candida albicans; Schiff bases; Staphylococcus aureus; anionic ligands; breast cells; tetrahedral.